«БЕДНЫЙ» ОВАРИАЛЬНЫЙ ОТВЕТ В ПРОГРАММАХ ЭКО


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Цель. Проведение систематического анализа данных, имеющихся в современной литературе, по этиологии, патогенезу, факторам риска, критериям диагностики и лечения «бедного» овариального ответа.

Полный текст

Доступ закрыт

Об авторах

Инна Владимировна ТЕТЕРИНА

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Email: i_teterina@oparina4.ru
аспирант отделения вспомогательных технологий в лечении бесплодия 117997, Россия, Москва, ул. Академика Опарина, д. 4

Роза Эдуардовна ВАНЯН

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Email: r_vanyan@oparina4.ru
аспирант отделения вспомогательных технологий в лечении бесплодия 117997, Россия, Москва, ул. Академика Опарина, д. 4

Елена Анатольевна КАЛИНИНА

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Email: e_kalinina@oparina4.ru
доктор медицинских наук, руководитель отделения вспомогательных технологий в лечении бесплодия 117997, Россия, Москва, ул. Академика Опарина, д. 4

Наталия Витальевна ДОЛГУШИНА

ФГБУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздрава России

Email: n_dolgushina@oparina4.ru
доктор медицинских наук, руководитель Службы научно-организационного обеспечения 117997, Россия, Москва, ул. Академика Опарина, д. 4

Список литературы

  1. Boudjenah R., Molina-Gomes D., Torre A., Bergere M., Bailly M., Boitrelle F. et al. Genetic polymorphisms influence the ovarian response to rFSH stimulation in patients undergoing in vitro fertilization programs with ICSI. PLoS One. 2012; 7(6): e38700.
  2. Steptoe P.C., Edwards R.G. Birth after the reimplantation of a human embryo. Lancet. 1978; 2 (8085): 366.
  3. Kamble L., Gudi A., Sha A., Homburg R. Poor responders to controlled ovarian hyperstimulation for in vitro fertilisation (IVF). Hum. Fertil. 2011; 14(4): 230-45.
  4. Ulug U., Ben-Shlomo I., Turan E., Erden H.F., Akman M.A., Bahceci M. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod. Biomed. Online. 2003; 6: 439-43.
  5. Badawy A., Wageah A., El Gharib M., Osman E.E. Prediction and diagnosis of poor ovarian response: the dilemma. J. Reprod. Infertil. 2011; 12(4): 241-8.
  6. Society for Assisted Reproductive Technology. American Society for Reproductive Medicine. Assisted reproductive technology in the United States: 2001 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology registry. Fertil. Steril. 2007; 87(6): 1253-66.
  7. Ferraretti A.P., La Marca A., Fauser B.C., Tarlatzis B., Nargund G., Gianaroli L.; ESHRE working group on Poor Ovarian Response Definition. ESHRE consensus on the definition of ‘poor response’ to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum. Reprod. 2011; 26(7): 1616-24.
  8. Loutradis D., Vomvolaki E., Drakakis P. Poor responder protocols for in-vitro fertilization: options and results. Curr. Opin. Obstet. Gynecol. 2008; 20(4): 374-8.
  9. Shaker A.G., Fleming R., Jamieson M.E., Yates R.W., Coutts J.R. Absence of effect of adjuvant growth hormone therapy on follicular responses to exogenous gonadotropins in women: normal and poor responders. Fertil. Steril. 1992; 58(5): 919-23.
  10. Toth T.L., Awwad J.T., Veeck L.L., Jones H.W. Jr., Muasher S.J. Suppression and flare regimens of gonadotropin-releasing hormone agonist. Use in women with different basal gonadotropin values in an in vitro fertilization program. J. Reprod. Med. 1996; 41(5): 321-6.
  11. Venetis C.A., Kolibianakis E.M., Tarlatzi T.B., Tarlatzis B.C. Evidence-based management of poor ovarian response. Ann. N. Y. Acad. Sci. 2010; 1205: 199-206.
  12. Gorgy A., Taranissi M. Defining and predicting the poor responder. Fertil. Steril. 2001; 75(1): 226-7.
  13. Pahdi N., Gupta S., Mahla A., Latha M., Varma T. Demographic characteristics and clinical profile of poor responders in IVF/ ICSI: a comparative study. J. Hum. Reprod. Sci. 2010; 3(2): 91-4.
  14. Moncayo R., Moncayo H., Dapunt O. Immunological risks of IVF. Lancet. 1990; 335 (8682): 180.
  15. Kokcu A., Yavuz E., Celik H., Bildircin D. A panoramic view to relationships between reproductive failure and immunological factors. Arch. Gynecol. Obstet. 2012; 286(5): 1283-9.
  16. Zou S.H., Zhang P., Song D.P., Li B., Wu R.Y. Impact of antiovarian antibodies (AOA) on ovarian responsiveness in vitro fertilization and embryo transfer. Neuro Endocrinol. Lett. 2008; 29(6): 949-52.
  17. Poppe K., Glinnoer D., Tournaye H., Devroey P., van Steirteghem A., Kaufman L., Velkeniers B. Assisted reproduction and thyroid autoimmunity: an unfortunate combination? J. Clin. Endocrinol. Metab. 2003; 88(9): 4149-52.
  18. Pires E.S., Meherji P.K., Vaidya R.R., Parikh F.R., Ghosalkar M.N., Khole V.V. Specific and sensitive immunoassay detects multiple anti-ovarian antibodies in women with infertility. J. Histochem. Cytochem. 2007; 55: 1181-90.
  19. Haller-Kikkatalo K., Salumets A., Uibo R. Review on autoimmune reactions in female infertility: antibodies to follicle stimulating hormone. Clin. Dev. Immunol. 2012; 2012: 762541.
  20. Koyama K., Hasegawa A., Mochida N., Calongos G. Follicular dysfunction induced by autoimmunity to zona pellucida. Reprod. Biol. 2005; 5(3): 269-78.
  21. Haller K., Salumets A., Uibo R. Anti-FSH antibodies associate with poor outcome of ovarian stimulation in IVF. Reprod. Biomed. Online. 2008; 16(3): 350-5.
  22. Layman L.C. Editorial: BMP15-the first true ovarian determinant gene on the X-chromosome? J. Clin. Endocrinol. Metab. 2006; 91: 1673-6.
  23. Greb R.R., Behre H.M., Simoni M. Pharmacogenetics in ovarian stimulation - current concepts and future options. Reprod. Biomed. Online. 2005; 11: 589-600.
  24. Kevenaar M.E., Themmen A.P., Laven J.S., Sonntag B., Fong S.L., Uitterlinden A.G. et al. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum. Reprod. 2007; 22: 1547-54.
  25. Josso N., Belville C., di Clemente N., Picard J.Y. AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum. Reprod. Update. 2005; 11(4): 351-6.
  26. Zamzami N., Kroemer G. p53 in apoptosis control: an introduction. Biochem. Biophys. Res. Commun. 2005; 331(3): 685-7.
  27. Жахур Н.А. Дифференцированная тактика лечения больных с преждевременной недостаточностью яичников. АГ-инфо. 2012; 1: 38-42.
  28. Gleicher N., Barad D.H. The FMR1 gene as regulator of ovarian recruitment and ovarian reserve. Obstet. Gynecol. Surv. 2010; 65(8): 523-30.
  29. Gleicher N., Weghofer A., Oktay K., Barad D. Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod. Biomed. Online. 2009; 19(3): 385-90.
  30. Persani L., Rossetti R., Cacciatore C., Bonomi M. Primary ovarian insufficiency: X chromosome defects and autoimmunity. J. Autoimmun. 2009; 33: 35-41.
  31. Moore R.K., Shimasaki S. Molecular biology and physiological role of the oocyte factor, BMP-15. Mol. Cell. Endocrinol. 2005; 234(1-2): 67-73.
  32. Mifsud A., Ramirez S., Yong E.L. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J. Clin. Endocrinol. Metab. 2000; 85: 3484-8.
  33. Lanasa M., Hogge W., Hoffman E. Sex Chromosome Genetics ‘99. The X chromosome and recurrent spontaneous abortions: the significance of transmanifesting carriers. Am. J. Hum. Genet. 1999; 64(4): 934-8.
  34. Sato K., Uehara S., Hashiyada M. Significance of skewed X-chromosome inactivation in premature ovarian failure. Am. J. Med. Genet. 2004; 130: 240-4.
  35. Johnson N.P., Bagrie E.M., Coomarasamy A., Bahattaacharya S., Shelling A.N., Jessop S. et al. Ovarian reserve tests for predicting fertility outcomes for assisted reproductive technology: the International Systematic Collaboration of Ovarian Reserve Evaluation protocol for a systematic review of ovarian reserve test accuracy. Br. J. Obstet. Gynaecol. 2006; 113(12): 1472-80.
  36. Gardner D., Weissman A., Howles C., Shoham Z., eds. Textbook of assisted reproductive techniques: laboratory and clinical perspectives. 2nd ed. London: Taylor & Francis; 2004.
  37. Cook C.L., Siow Y., Taylor S., Fallat M.E. Serum Müllerianinhibiting substance levels during normal menstrual cycles. Fertil. Steril. 2002; 73(4): 859-61.
  38. Nelson S.M., Yates R.W., Lyall H., Jamieson M., Traynor I., Gaudoin M. et al. Anti- Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod. 2009; 24(4): 867-75.
  39. Forges T., Monnier-Barbarino P., Guillet-May F., Faure G.C., Béné M.C. Corticosteroids in patients with antiovarian antibodies undergoing in vitro fertilization: a prospective pilot study. Eur. J. Pharmacol. 2006; 62: 699-705.
  40. Klinkert E.R., Broekmans F.J., Looman C.W., Habbema J.D., te Velde E. R. Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Hum. Reprod. 2005; 20: 611-5.
  41. Lekamge D.N., Lane M., Gilchrist R.B., Tremellen K.P. Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. J. Assist. Reprod. Genet. 2008; 25(11-12): 515-21.
  42. De Placido G., Alviggi C., Mollo A., Strina I., Varricchio M.T., Molis M. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum. Reprod. 2000; 15: 17-20.
  43. Eskandar M., Jaroudi K., Jambi A., Archibong E. I., Coskun S., Sobande A.A. Is recombinant follicle-stimulating hormone more effective in IVF poor responders than human menopausal gonadotrophins? Med. Sci. Monit. 2004; 10(1): PI6-9.
  44. Al-Inany H., Aboulghar M.A., Mansour R.T., Serour G.I. Ovulation induction in the new millennium: recombinant follicle-stimulating hormone versus human menopausal gonadotropin. Gynecol. Endocrinol. 2005; 20: 161-9.
  45. Rombauts L., Suikkari A.M., MacLachlan V., Trounson A.O., Healy D.L. Recruitment of follicles by recombinant human follicle-stimulating hormone commencing in the luteal phase of the ovarian cycle. Fertil. Steril. 1998; 69: 665-9.
  46. Kucuk T., Sozen E. Luteal start of exogenous FSH in poor responder women. J. Assist. Reprod. Genet. 2007; 24: 635-8.
  47. Kansal Kalra S., Ratcliffe S., Gracia C.R., Martino L., Coutifaris C., Barnhart K.T. Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders. Reprod. Biomed. Online. 2008; 17: 745-50.
  48. Garcia-Velasco J.A., Isaza V., Requena A., Martinez-Salazar F.J., Landazabal A., Remohi J. et al. High doses of gonadotrophins combined with stop versus non-stop protocol of GnRH analogue administration in low responder IVF patients: a prospective, randomized, controlled trial. Hum. Reprod. 2000; 15: 2292-6.
  49. Surrey E.S. Management of the poor responder: the role of GnRH agonists and antagonists. J. Assist. Reprod. Genet. 2007; 24: 613-9.
  50. Morgia F., Sbracia M., Schimberni M., Giallonardo A., Piscitelli C., Giannini P. et al. A controlled trial of natural cycle versus microdose gonadotropin-releasing hormone analog flare cycles in poor responders undergoing in vitro fertilization. Fertil. Steril. 2004; 81: 1542-7.
  51. Kemeter P., Feichtinger W. Prednisolone supplementation to Clomid and/or gonadotrophin stimulation for in-vitro fertilization—a prospective randomized trial. Hum. Reprod. 1986; 1(7): 441-4.
  52. Ubaldi F., Rienzi L., Ferrero S., Anniballo R., Iacobelli M., Cobellis L. et al. Low dose prednisolone administration in routine ICSI patients does not improve pregnancy and implantation rates. Hum. Reprod. 2002; 17(6): 1544-7.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2013

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах